Related Experiment Video

Updated: Apr 30, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

8.8K

Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma

Yoshiko Kaku1, Hisao Nagaya, Ayako Tsuchiya

  • 1Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Cancer Science
|April 24, 2014
PubMed

Insights

A new drug candidate, HUHS1015, shows promise in treating malignant pleural mesothelioma. It effectively reduced cancer cell viability and suppressed tumor growth in preclinical studies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Malignant pleural mesothelioma is an aggressive cancer with limited treatment options.
  • There is a need for novel therapeutic agents to improve patient outcomes.

Purpose of the Study:

  • To evaluate the anticancer potential of a novel naftopidil analogue, HUHS1015.
  • To investigate the mechanisms of action and in vivo efficacy of HUHS1015 against malignant pleural mesothelioma.

Main Methods:

  • Assessed the effect of HUHS1015 on cell viability in multiple mesothelioma cell lines.
  • Investigated apoptosis and necrosis induction.
  • Analyzed mRNA expression of key apoptosis-related genes (Puma, Hrk, Noxa).
  • Evaluated tumor growth suppression in a mouse xenograft model.

Main Results:

  • HUHS1015 significantly reduced cell viability in MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452 cells.
  • The drug induced both necrosis and apoptosis in MSTO-211H and NCI-H2052 cells.
  • HUHS1015 upregulated pro-apoptotic genes (Puma, Hrk, Noxa), indicating mitochondrial apoptosis.
  • Significant suppression of tumor growth was observed in vivo.

Conclusions:

  • HUHS1015 demonstrates potent in vitro and in vivo anticancer activity against malignant pleural mesothelioma.
  • The compound induces apoptosis through the mitochondrial pathway.
  • HUHS1015 represents a promising candidate for further development as a mesothelioma therapeutic.
Keywords:
ApoptosisBcl-2 familyHUHS1015malignant pleural mesotheliomasynthetic anticancer compound

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.3K
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K